Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;38(3):496-501.
doi: 10.1002/mds.29330. Epub 2023 Jan 27.

Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases

Luca Marsili  1 , Kevin R Duque  1 , Nathan Gregor  1 , Elhusseini Abdelghany  1 , Jesus Abanto  1 , Andrew P Duker  1 , Matthew C Hagen  2 , Alberto J Espay  1 , Matteo Bologna  3   4
Affiliations

Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases

Luca Marsili et al. Mov Disord. 2023 Mar.

Abstract

Background: Bradykinesia is a cardinal feature in parkinsonisms. No study has assessed the differential features of bradykinesia in patients with pathology-proven synucleinopathies and tauopathies.

Objective: We examined whether bradykinesia features (speed, amplitude, rhythm, and sequence effect) may differ between pathology-proven synucleinopathies and tauopathies.

Methods: Forty-two cases who underwent autopsy were included and divided into synucleinopathies (Parkinson's disease and dementia with Lewy bodies) and tauopathies (progressive supranuclear palsy). Two raters blinded to the diagnosis retrospectively scored the Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III and Modified Bradykinesia Rating Scale on standardized videotaped neurological examinations. Bradykinesia scores were compared using the Mann-Whitney test and logistic regression models to adjust for disease duration.

Results: Demographic and clinical parameters were similar between synucleinopathies and tauopathies. There were no differences between speed, amplitude, rhythm, and sequence effect in synucleinopathies and tauopathies in unadjusted comparisons and adjusted models (all P > 0.05).

Conclusions: Clinical bradykinesia features do not distinguish the underlying neuropathology in neurodegenerative parkinsonisms. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: bradykinesia; neurodegeneration; neuropathology; synucleinopathy; tauopathy.

PubMed Disclaimer

References

    1. Espay AJ, Beaton DE, Morgante F, Gunraj CA, Lang AE, Chen R. Impairments of speed and amplitude of movement in Parkinson's disease: a pilot study. Mov Disord 2009;24(7):1001-1008.
    1. Espay AJ, Giuffrida JP, Chen R, et al. Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease. Mov Disord 2011;26(14):2504-2508.
    1. Heldman DA, Espay AJ, LeWitt PA, Giuffrida JP. Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease. Parkinsonism Relat Disord 2014;20(6):590-595.
    1. Bologna M, Leodori G, Stirpe P, et al. Bradykinesia in early and advanced Parkinson's disease. J Neurol Sci 2016;369:286-291.
    1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30(12):1591-1601.

MeSH terms

LinkOut - more resources